Keros Therapeutics is a brand that is dedicated to delivering significant clinical benefits to patients with hematological, pulmonary, and cardiovascular disorders. They focus on developing differentiated product candidates that target the transforming growth factor-beta (TGF-β) family of proteins, which play a crucial role in the growth, repair, and maintenance of various tissues. In their hematology franchise, Keros Therapeutics is developing two product candidates, KER-050 and KER-047, to treat ineffective hematopoiesis and functional iron deficiency in myelodysplastic syndromes and myelofibrosis.

They also have KER-012, their lead product candidate in the pulmonary and cardiovascular franchise, which is being developed for the treatment of pulmonary arterial hypertension. Additionally, KER-065, their fourth product candidate, is focused on neuromuscular diseases, specifically Duchenne muscular dystrophy. Keros Therapeutics leverages their expertise in TGF-β biology to fuel their research engine and bring innovative treatment options to patients with high unmet medical needs.

Their team of experienced professionals is dedicated to making a meaningful impact on patients' lives